SCHEMBL3780586

SCHEMBL3780586

CCOC(=O)c1cc(F)c(O)c([N+](=O)[O-])c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 1/20 0.58
KMT2A Q03164 2/20 0.52
NPC1 O15118 2/20 0.51
ALDH1A1 P00352 4/20 0.51
MAPT P10636 4/20 0.51
RAB9A P51151 2/20 0.51
PKM P14618 1/20 0.51
CRHBP P24387 1/20 0.51
CRHR2 Q13324 1/20 0.51
LMNA P02545 2/20 0.50
POLB P06746 2/20 0.50
KDM4E B2RXH2 1/20 0.50
PTPN11 Q06124 1/20 0.49
CA12 O43570 1/20 0.49
CA1 P00915 1/20 0.49
CA2 P00918 1/20 0.49
CA7 P43166 1/20 0.49
CA9 Q16790 1/20 0.49
CA14 Q9ULX7 1/20 0.49
PTGER4 P35408 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5924443 0.90 ESR1 (0.69) ESR1KMT2ANPC1ALDH1A1MAPT
SCHEMBL8729045 0.88 ESR1 (0.60) ESR1KMT2ANPC1ALDH1A1MAPT
SCHEMBL27248745 0.87 KMT2A (0.53) ESR1KMT2ANPC1ALDH1A1MAPT
SCHEMBL13011084 0.85 ESR1 (0.60) ESR1KMT2ANPC1ALDH1A1MAPT
SCHEMBL31750379 0.84 KDM4E (0.51) ESR1KMT2AALDH1A1MAPTRAB9A
SCHEMBL753386 0.84 KDM4E (0.51) ESR1KMT2AALDH1A1MAPTRAB9A
SCHEMBL13011349 0.83 ESR1 (0.58) ESR1KMT2ANPC1ALDH1A1MAPT
SCHEMBL4291025 0.83 ESR1 (0.58) ESR1KMT2ANPC1ALDH1A1MAPT
SCHEMBL25930668 0.82 NPC1 (0.56) ESR1KMT2ANPC1ALDH1A1MAPT
SCHEMBL309910 0.82 ESR1 (0.56) ESR1KMT2ANPC1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100324017-A1 ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2010-12-23 US disclosed
US-20100324017-A1 ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2010-12-23 US disclosed
US-20100324017-A1 ACYLGUANIDINE DERIVATIVE ASTELLAS PHARMA INC. (JP) 2010-12-23 US disclosed
EP-2119704-A1 ACYLGUANIDINE DERIVATIVE Astellas Pharma Inc. (JP) 2009-11-18 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100324017-A1 ACYLGUANIDINE DERIVATIVE HTR5A, GRM5, HTR1E ESR1 1644/4885KMT2A 1785/4885NPC1 1574/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.